Can elevated uric acid reduce endothelial nitric oxide and raise cardiometabolic risk?

Uric acid plays a complex role in the body, acting as an antioxidant in the blood but becoming a significant pro-oxidant and pro-inflammatory agent when it enters cells. This transition is a critical driver of vascular and metabolic dysfunction, particularly as it relates to blood pressure regulation and overall cardiometabolic health.

Clinical and effectiveness evidence

Large-scale longitudinal studies demonstrate a clear link between elevated uric acid and the development of hypertension.

• Hypertension risk: Hyperuricemia is associated with a 2% to 15% increased risk (HR 1.02–1.15) of developing hypertension, particularly in middle-aged adults.
• Obesity mediation: Approximately 53% of the effect of uric acid on blood pressure is mediated by obesity, suggesting a strong interplay between body weight and urate levels.
• Treatment outcomes: Interventions using urate-lowering therapies (ULT), such as allopurinol, have been shown to reduce both systolic and diastolic blood pressure, reinforcing the causal nature of this relationship.
• Sex-specific risk: In women, the risk of hyperuricemia is significantly higher when metabolic syndrome or obesity is present (OR 7.24 compared to 2.90 in men), potentially due to the synergistic effects of metabolic dysfunction and age-related hormonal changes.

Mechanistic explanations

The transition of uric acid into the intracellular environment triggers a cascade of events that impair blood vessel function and promote systemic inflammation.

• Nitric oxide (NO) depletion: Pathological uric acid levels (>7 mg/dL) activate xanthine oxidase and NADPH oxidase, generating reactive oxygen species (ROS). These ROS "scavenge" nitric oxide, converting it into peroxynitrite, while simultaneously uncoupling the eNOS enzyme so it produces more superoxide instead of beneficial NO.
• Vascular dysfunction: Uric acid further inhibits eNOS activity by promoting inhibitory phosphorylation (Thr495) and disrupting the insulin/Akt pathway. This lack of NO results in impaired flow-mediated dilation (FMD) and increased vascular stiffness.
• Inflammatory signaling: Intracellular uric acid activates the NLRP3 inflammasome and the NF-κB pathway. This leads to the release of potent pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, which are reflected in elevated high-sensitivity C-reactive protein (hs-CRP) levels.

Bottom line

Elevated uric acid is a robust driver of hypertension and cardiometabolic risk. It acts through clear mechanistic pathways involving nitric oxide depletion, oxidative stress, and the activation of the NLRP3 inflammasome, making it a critical biomarker for vascular health, especially in middle-aged women.